Tenax Pauses LEVEL-2 Enrollment to Narrow TNX-103 Patient Selection
Tenax pauses LEVEL-2 enrollment to refine TNX-103 patient selection after the initial trial missed its primary walking distance endpoint.
SYCUME meets primary endpoint in Phase 3 trial for inactive thyroid eye disease
SYCUME met its Phase 3 primary endpoint for inactive thyroid eye disease, showing significant proptosis reduction versus placebo at...
FDA Approves Tecentriq for Stage III dMMR Colon Cancer
FDA approves Tecentriq for stage III dMMR colon cancer as adjuvant treatment. ATOMIC trial showed improved disease-free survival when...
When the Factory Holds Up the Approval, Your Sites Are Already Paying for It
FDA extended Novo Nordisk's denecimig review over manufacturing remediation. Here's what sponsor clinops teams must do before the new...
The Eye as a Biomarker: Why Retinal AI Could Reshape How Trials Screen and Stratify Pregnant Patients
A Nature Biotechnology retinal AI model detects preeclampsia and gestational hypertension risk non-invasively, and its trial implications go far...
Ribo Files EU Trial Application for INHBE-Targeting Obesity Drug RBD3133
Ribo files EU Trial Application for RBD3133, an siRNA targeting INHBE for obesity treatment backed by human genetic evidence.
Jupiter Neurosciences Doses First Parkinson’s Patient in JOTROL Phase 2a Trial
Jupiter Neurosciences doses first Parkinson's patient in JOTROL Phase 2a trial, testing whether enhanced resveratrol achieves therapeutic brain concentrations.
Remibrutinib reduces relapse rates versus teriflunomide in Phase 3 MS trials
Remibrutinib reduces relapse rates versus teriflunomide in Phase 3 MS trials REMODEL-1 and REMODEL-2, with results presented at MSToronto2026.
FDA approves Rhapsido (remibrutinib) for symptomatic dermographism
FDA approves Rhapsido (remibrutinib) for symptomatic dermographism, the first prescription treatment for adults with the condition inadequately controlled by...
Where Clinical Trials Have Never Been: Rovia’s Case for Building Research Infrastructure in Forgotten Communities
Rovia grew a site network in places where sponsors needed patient access. Now sponsors are coming to him.